Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVL-103
- Development stage
- Preclinical
- Lead developer
- Beijing Xunsheng Biomedical Research
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AVL-103 is a bivalent mRNA-based therapeutic vaccine being developed by Beijing Xunsheng Biomedical Research (Aeonvital) for the treatment of genital warts (condylomata acuminata) and respiratory papillomatosis. The vaccine is designed to target human papillomavirus (HPV) types associated with these conditions. Administered via intramuscular injection, AVL-103 is intended to induce robust immune responses against HPV antigens to clear persistent infections and treat associated lesions. It is currently in preclinical development, with an Investigational New Drug (IND) application expected in 2027.
Beyond the preview
Go deeper on AVL-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVL-103.